Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


TGA tightens grip on opioids

Posted 20 November 2020

Sweeping reforms by the TGA to minimise harm caused by opioid prescription medicines have expanded further to include the makers of generic opioids who must now update their consumer and product information - bringing them in line with the same tough rules that apply to product innovators.

Under the changes, the sponsors of generic opioids will have to include new indications and associated warnings on consumer medicines information and product information.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Picking the path out of Covid
Now is not the time for leaders to play it safe
Special Report
Aust Covid Vaccine Tracker
UPDATE: Gilead hits back at WHO over remdesivir
Approvals Action
Trio of new drugs on ARTG
Roche, Seqirus, Clinuvel enlarge local portfolios